Ness Ziona, Israel, March 1, 2007 – Kamada (TASE: KMDA), an Israeli bio-pharmaceutical company which develops, manufactures and markets prescription drugs, announced that it is beginning the third and last stage of clinical trials before licensure of its flagship product Alpha-1 Antitrypsin (AAT), also known as Alpha-1 Proteinase Inhibitor (API). The clinical trial, which follows FDA-approved protocol, will include 50 patients from the U.S.
